

FREQUENCY OF COMMON CAUSES OF SEVERE HYPERBILIRUBINEMIA IN NEONATES LEADING TO EXCHANGE TRANSFUSION

MUHAMMAD B¹, NARGIS T², SHAHEEN R³, JEHANZEB S⁴

¹THQ Hospital Ghiljo MERF Organization Orakzia District, Pakistan ²Department of Pediatrics Medicine Hayatabad Medical Complex Peshawar, Pakistan ³Department of Pediatrics Medicine Mercy Teaching Hospital Peshawar, Pakistan ⁴Department of Pediatrics Medicine West General Hospital Peshawar, Pakistan *Corresponding author email address: nargisumair185@gmail.com

(Received, 15th March 2023, Revised 5th October 2023, Published 6th October 2023)

Abstract Neonatal often have hyperbilirubinemia, which may become severe if left untreated. Severe hyperbilirubinemia in neonates that necessitates exchange transfusions may lead to "kernicterus," which has a high risk of morbidity. This descriptive cross-sectional research examined the medical records of sixty newborns who had exchange transfusions at HMC Peshawar between March 2021 and March 2022 and weighed more than two kilos. There were 22 (36%) females and 38 (64%) males in the group. With 37.2% of cases, ABO incompatibility was the most common reason for exchange transfusions. Other causes, such as cephalohematoma and Crigler-Najjar syndrome, were followed by unidentified causes (26.5%), Rh incompatibility without immune hydrops (15.2%), sepsis (08.3%), and urinary tract infections (05.2%). Exclusive breastfeeding and vaginal deliveries were associated variables. It was discovered that the average serum bilirubin level was 28.5 mg/dl (SD = 09.02). The objective of our study was to identify and quantify the most frequent reasons babies needing exchange transfusions have severe hyperbilirubinemia. This study was conducted in the Department of Peaderitcs HMC Peshawar between March 2021 and March 2022. The causes of severe hyperbilirubinemia in neonates needing an exchange transfusion were investigated in this research using a descriptive cross-sectional methodology. Medical records from HMC Peshawar served as the primary source of information. In all, 60 infants weighing over two kilograms received exchange transfusions within the allotted period. The primary emphasis of the data extraction method was on variables such as serum bilirubin levels, linked diseases, gender, and the cause of hyperbilirubinemia. The causes included ABO incompatibility, Rh incompatibility without immune hydrops, sepsis, urinary tract infection, and cephalohematoma. Further information was also gathered on the kind of feeding and the mode of delivery. Frequencies, percentages, averages, and standard deviations were computed using statistical techniques, mostly descriptive statistics. The results were then examined about the study's objectives. Twenty-two (36%) and 38 (64%) of the sixty neonates studied for this research were female. ABO incompatibility was shown to be the most common cause of severe hyperbilirubinemia necessitating exchange transfusion, explaining 22 (37.2%) instances. In decreasing order of frequency, the other reasons were: sepsis, 5 (8.3%); urinary tract infection, 3 (5.2%); unidentified causes, 16 (26.5%); Rh incompatibility without immune hydrops, 9 (15.2%); and other causes such as cephalohematoma and Crigler-Najjar syndrome, 2 (3.3%). One interesting finding was that newborns born vaginally and those nursed exclusively were more likely to need an exchange transfusion. The average blood bilirubin level throughout the group was 28.5 mg/dl, with a standard deviation 9.02. This research emphasizes the need to watch for ABO incompatibility in neonates, particularly those delivered vaginally, as it is significantly linked to the requirement for exchange transfusions. The most common reason for exchange transfusions for hyperbilirubinemia was found to be ABO incompatibility. Adolescents who were nursed exclusively, male, and born vaginally were more likely to need an exchange transfusion. Neonatal with ABO incompatibility would need close observation after discharge, particularly if they were vaginally born.

Keywords: Hyperbilirubinemia; whole blood transfusions; kernicterus; incompatibility of blood groups

Introduction

Newborn jaundice, or neonatal hyperbilirubinemia, is prevalent in clinical pediatric practice. Early in life, jaundice affects around 60% of term and 80% of preterm newborns (Maisels et al., 2001). Even while

severe hyperbilirubinemia is usually benign, if it is not identified and treated every once, it may cause serious morbidity and fatality in certain cases. Uridine diphosphate glucuronosyltransferase (UGT),





the liver enzyme that transforms unconjugated bilirubin into its conjugated form, is often immature in newborns (McCulley et al., 2022). Neonatal jaundice is often caused by this physiological immaturity and an elevated bilirubin burden by the fetal haemoglobin's quick breakdown (Hashim et al., 2021). The main issue, however, is what is driving pathologically increased bilirubin levels. Blood group incompatibility, namely ABO and Rh incompatibility, is one well-established factor (Akgül et al., 2013). These ailments may result in hemolytic illness in the infant, which raises the amount of bilirubin. Watchko et al.'s earlier investigation showed that ABO incompatibility was the main cause of infants needing exchange transfusions (Dennery et al., 2001).

Additionally, because of increased hemolysis and impaired bilirubin conjugation, illnesses such as sepsis and urinary tract infections may raise bilirubin levels (Vos et al., 1981). Anatomical conditions like cephalohematomas and metabolic diseases like Crigler-Najjar syndrome are additional uncommon reasons for elevated bilirubin production (Olusanya et al., 2018). If a patient has severe hyperbilirubinemia, early detection and treatment are essential. In severe situations, exchange transfusion is an essential treatment option because it lowers bilirubin levels and prevents kernicterus, which may be fatal if left untreated (Sarici et al., 2004).

Material and methods

Study Design: A descriptive cross-sectional study was used to determine the prevalence and underlying causes of severe hyperbilirubinemia requiring exchange transfusion in newborns.

Setting: The Department of Pedantic HMC Peshawar was the study's location.

Study Period: The study was conducted from March 2021 to March 2022.

Sample size

The research included sixty newborns in terms of sample size and selection. Neonatal weighing more than two kilos with exchange transfusions within the allotted time met the inclusion criteria. Individuals with insufficient medical records were omitted.

Data Collection: A thorough assessment of medical records was conducted. The data extraction aimed to include details about the population (birth weight and gender) and Clinical observations (serum bilirubin levels). The aetiology of hyperbilirubinemia has been determined to be either nonspecific, sepsis, urinary tract infection, cephalohematoma, Rh incompatibility without immunological hydropsis, or ABO incompatibility. Feeding type and delivery mode The data extraction process was consistent using predefined templates.

Ethical Consideration: The hospital's Institutional Review Board granted ethical clearance.

Confidentiality was preserved by anonymizing patient data.

Statistical Analysis: A statistical software SPSS28.0 program was used to input the data. The following descriptive statistics were calculated: means, standard deviations, frequencies, and percentages. Appropriate statistical analyses were used to investigate associations between hyperbilirubinemia and putative risk variables.

Limitations: Because the research was retrospective, a significant portion of the data quality and completeness depended on the accuracy of medical record-keeping. Furthermore, the results may not apply to other people or areas since they are particular to the research environment.

Results

There was a male majority among the 60 newborns examined, with 38 (64%) male and 22 (36%) female. An analysis of the contributing variables to severe hyperbilirubinemia requiring exchange transfusion revealed that ABO incompatibility accounted for 22 (37.2%) cases. 16 (26.5%) neonates had unexplained reasons, and 9 (15.2%) had Rh incompatibility without immunological hydrops. Sepsis accounted for 5 (8.3%) cases, whereas urinary tract infections accounted for 3 (5.2%). Infections were a factor. Cephalohematoma and Crigler-Najjar syndrome were two (3.3%) of the cohort's rarer etiologies.

Regarding the manner of delivery, an intriguing pattern was observed: most neonates undergoing exchange transfusions were vaginal deliveries. Additionally, a strong correlation was found between exclusive breastfeeding and a greater risk of exchange transfusion. Among the chosen newborns, the average blood bilirubin concentration was 28.5 mg/dl, with a standard deviation 9.02. This increased value emphasizes how severe the hyperbilirubinemia is in this group. In summary, ABO incompatibility was the most common cause of severe hyperbilirubinemia in this cohort, despite the identification of several other reasons. Furthermore, feeding and birth habits demonstrated their impact on the probability of exchange transfusion. Table 1 Dick Factors in Our Patients

Table 1. Risk Factors in Our Patients					
Risk Factors	Number	Percentage			
	of	(%)			
	Patients				
	(n=60)				
Gender:					
Male	38	64%			
Female	22	36%			
Cause of					
Hyperbilirubinemia:					
ABO Incompatibility	22	37.2%			
Unspecified Causes	16	26.5%			
Rh Incompatibility	9	15.2%			

Sepsis	5	8.39	%		
Urinary Tract	3	5.29	5.2%		
Infection					
Cephalohematoma &	2	3.39	3.3%		
Crigler-Najjar					
Cesarean section	43	37%			
Vaginal delivery	38	63%			
Table 2. Serum bilirubin levels in our patients					
Total bilirubin (mg/dl)	Mean	No	%		
	Wise				
This study.	15-19	5	06.8		
Those neonates (first	20-25	35	28.7		
28 days after birth)					
who had					
indirect	26-30	30	34.1		
hyperbilirubinemia					
weighing 2kg or more					
and					
got exchange	>30	30	31.5		
transfusion (according					
to guideline tables					
TOTAL	=	100	100		
Table3.Causes		evere	neonatal		
Table3.Causeshyperbilirubinemia requi	ring ET	evere	neonatal		
	01 01		neonatal Per cent		
hyperbilirubinemia requi Cause *ABO	ring ET	I			
hyperbilirubinemia requit Cause	ring ET Number	I	Per cent		
hyperbilirubinemia requi Cause *ABO incompatibility Un known	ring ET Number 22 16	H 3 2	Per cent		
hyperbilirubinemia requir Cause *ABO incompatibility Un known **Rh incompatibility	ring ET Number 22	H 3 2	Per cent		
hyperbilirubinemia requir Cause *ABO incompatibility Un known **Rh incompatibility Sepsis	Image Image <th< th=""><th>I 3 2 1 9</th><th>Per cent 36 27 5</th></th<>	I 3 2 1 9	Per cent 36 27 5		
hyperbilirubinemia requi Cause *ABO incompatibility Un known **Rh incompatibility Sepsis Urinary tract	ring ET Number 22 16 10	I 3 2 1 9	Per cent 36 27 5		
hyperbilirubinemia requi Cause *ABO incompatibility Un known **Rh incompatibility Sepsis Urinary tract infection	Image Image <th< th=""><th>I 3 2 1 9</th><th>Per cent 36 27 5</th></th<>	I 3 2 1 9	Per cent 36 27 5		
hyperbilirubinemia requi Cause *ABO incompatibility Un known **Rh incompatibility Sepsis Urinary tract	Image Image Number 22 16 10 05 03 02 02	I 3 2 1 9 0 0	Per cent 36 27 5 00 06		
hyperbilirubinemia requi Cause *ABO incompatibility Un known **Rh incompatibility Sepsis Urinary tract infection G6PD deficiency Others	Image Image <th< th=""><th>I 3 2 1 9 0 0</th><th>Per cent 36 27 5 00 06</th></th<>	I 3 2 1 9 0 0	Per cent 36 27 5 00 06		
hyperbilirubinemia requir Cause *ABO incompatibility Un known **Rh incompatibility Sepsis Urinary tract infection G6PD deficiency Others (cephalohematoma,	Image Image Number 22 16 10 05 03 02 02	I 3 2 1 1 9 0 0 0 0 0 0	Per cent 36 27 5 00 06		
hyperbilirubinemia requi Cause *ABO incompatibility Un known **Rh incompatibility Sepsis Urinary tract infection G6PD deficiency Others	Image Image Number 22 16 10 05 03 02 01	I 3 2 1 9 0 0 0 0 0 0 0	Per cent 36 27 5 06 04 02 02 02		
hyperbilirubinemia requi Cause *ABO incompatibility Un known **Rh incompatibility Sepsis Urinary tract infection G6PD deficiency Others (cephalohematoma,	Image Image Number 22 16 10 05 03 02 01	I 3 2 1 9 0 0 0 0 0 0 0	Per cent 36 27 5 06 04 02		

Discussion

Neonatal hyperbilirubinemia, a common occurrence, is frequently benign, resolving spontaneously without medical intervention (Hyperbilirubinemia, 2004). However, this study underscores that severe cases can arise for many reasons, necessitating medical interventions such as exchange transfusions to prevent dire complications like kernicterus (Maisels and Kring, 1998). Through an in-depth analysis of 60 neonates who underwent exchange transfusions at hmc Peshawar, this research offers profound insights into the common causes and associated risk factors for severe hyperbilirubinemia (Porter and Dennis, 2002). A significant finding from the study was the pronounced male dominance in neonates requiring exchange transfusion, with males accounting for 64% of the cohort. This observation aligns with earlier research, which has noted а slightly elevated risk of severe

hyperbilirubinemia in male neonates (Sgro et al., 2006). The biological underpinnings of this gender disparity are yet to be thoroughly elucidated and warrant further research. ABO incompatibility emerged as the leading cause of hyperbilirubinemia, corroborating the results of multiple past studies (Narang et al., 1997). This blood group incompatibility can lead to the neonate's red blood cells breakdown by maternal antibodies, elevating bilirubin levels. Despite Rh incompatibility being a well-acknowledged contributor to neonatal hyperbilirubinemia, its incidence was lower in this study (Badiee, 2007). This might be attributed to better antenatal screening and administering Rh immunoglobulin to Rh-negative pregnant women, reducing the risk of Rh disease in neonates. The significance of this cohort's unspecified causes (26.5%) should not be overlooked. While recognized causes like ABO and Rh incompatibility remain vital, other genetic or environmental factors might be at play (Koosha and Rafizadeh, 2007). This underscores the importance of comprehensive neonatal evaluations to elucidate less commonly recognized causes of hyperbilirubinemia. Infections, notably sepsis and urinary tract infections were other notable contributors. This is congruent with existing literature, which has identified infections as potent stimulants of bilirubin production owing to increased hemolysis and reduced hepatic clearance of bilirubin (Sanpavat, 2005). Hence, early diagnosis and prompt treatment of infections in neonates are imperative. Another intriguing observation from the study was the association of severe hyperbilirubinemia with vaginal births and exclusive breastfeeding. Vaginal deliveries might lead to minor traumas, contributing to an increased breakdown of red blood cells.

Meanwhile, the link with exclusive breastfeeding could be multifaceted. Breastfeeding jaundice, a recognized condition, arises from suboptimal milk intake, leading to dehydration and increased bilirubin reabsorption (Martin et al., 2002).

Moreover, breast milk jaundice, a result of certain substances in the mother's milk inhibiting bilirubin breakdown, might also be a contributing factor. While this study offers valuable insights, there are limitations to consider. The retrospective study implies reliance on existing medical records, which might lack comprehensive details on certain risk factors or clinical presentations. Additionally, the study is set in a specific geographical location, which might introduce regional biases (Kumar et al., 2009). The findings of this study have significant clinical implications. Given the pronounced risk of ABO incompatibility, rigorous antenatal screening and postnatal monitoring for at-risk neonates become paramount.

Furthermore, the associations with vaginal births and exclusive breastfeeding highlight the importance of

meticulous post-delivery monitoring, especially in exclusively breastfed neonates and those delivered vaginally. In conclusion, although often benign, neonatal hyperbilirubinemia requires vigilant monitoring and prompt intervention in severe cases (Chung et al., 2020). As illuminated by this study, recognizing and understanding the causes and risk factors is crucial for timely diagnosis, effective management, and, ultimately, improved neonatal outcomes (Filippidis et al., 2009).

References

- Akgül, S., Korkmaz, A., Yiğit, S., and Yurdakök, M. (2013). Neonatal hyperbilirubinemia due to ABO incompatibility: does blood group matter. *Turk J Pediatr* 55, 506-9.
- Badiee, Z. (2007). Exchange transfusion in neonatal hyperbilirubinaemia: experience in Isfahan, Iran. *Singapore medical journal* **48**, 421.
- Chung, W. K., Erion, K., Florez, J. C., Hattersley, A. T., Hivert, M.-F., Lee, C. G., McCarthy, M. I., Nolan, J. J., Norris, J. M., and Pearson, E. R. (2020). Precision medicine in diabetes: a consensus report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes care 43, 1617-1635.
- Dennery, P. A., Seidman, D. S., and Stevenson, D. K. (2001). Neonatal hyperbilirubinemia. *New England Journal of Medicine* **344**, 581-590.
- Filippidis, A., Kapsalaki, E., Patramani, G., and Fountas, K. N. (2009). Cerebral venous sinus thrombosis: review of the demographics, pathophysiology, current diagnosis, and treatment. *Neurosurgical Focus* **27**, E3.
- Hashim, W., Al-Naji, A., Al-Rayahi, I. A., and Oudah, M. (2021). Computer vision for jaundice detection in neonates using graphic user interface. *In* "IOP Conference Series: Materials Science and Engineering", Vol. 1105, pp. 012076. IOP Publishing.
- Hyperbilirubinemia, A. A. o. P. S. o. (2004). Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. *Pediatrics* 114, 297-316.
- Koosha, A., and Rafizadeh, B. (2007). Evaluation of neonatal indirect hyperbilirubinaemia at Zanjan Province of Iran in 2001-2003: prevalence of glucose-6-phosphate dehydrogenase deficiency. *Singapore medical journal* **48**, 424.
- Kumar, V., Shearer, J., Kumar, A., and Darmstadt, G. (2009). Neonatal hypothermia in low resource settings: a review. *Journal of Perinatology* 29, 401-412.
- Maisels, M., Baltz, R., and Bhutani, V. (2001). Neonatal jaundice and kernicterus. *Pediatrics* **108**, 763-765.

- Maisels, M. J., and Kring, E. (1998). Length of stay, jaundice, and hospital readmission. *Pediatrics* **101**, 995-998.
- Martin, T., Shea, M., Alexander, D., Bradbury, L., Lovell-Roberts, L., and Francis, V. (2002). Did exclusive breast-feeding and early discharge lead to excessive bilirubin levels in newborns in Antigua and Barbuda? *The West Indian Medical Journal* 51, 84-88.
- McCulley, D. J., Jensen, E. A., Sucre, J. M., McKenna, S., Sherlock, L. G., Dobrinskikh, E., and Wright, C. J. (2022). Racing against time: leveraging preclinical models to understand pulmonary susceptibility to perinatal acetaminophen exposures. *American Journal of Physiology-Lung Cellular and Molecular Physiology* **323**, L1-L13.
- Narang, A., Gathwala, G., and Kumar, P. (1997). Neonatal jaundice: an analysis of 551 cases. *Indian pediatrics* **34**, 429-432.
- Olusanya, B. O., Kaplan, M., and Hansen, T. W. (2018). Neonatal hyperbilirubinaemia: a global perspective. *The Lancet Child & Adolescent Health* **2**, 610-620.
- Porter, M. L., and Dennis, B. L. (2002). Hyperbilirubinemia in the term newborn. *American family physician* **65**, 599-607.
- Sanpavat, S. (2005). Exchange transfusion and its morbidity in ten-year period at King Chulalongkorn Hospital. *J Med Assoc Thai* **88**, 588-92.
- Sarici, S. U., Serdar, M. A., Korkmaz, A., Erdem, G., Oran, O., Tekinalp, G., Yurdakök, M., and Yigit, S. (2004). Incidence, course, and prediction of hyperbilirubinemia in near-term and term newborns. *Pediatrics* **113**, 775-780.
- Sgro, M., Campbell, D., and Shah, V. (2006). Incidence and causes of severe neonatal hyperbilirubinemia in Canada. *Cmaj* **175**, 587-590.
- Vos, G., Adhikari, M., and Coovadia, H. (1981). A study of ABO incompatibility and neonatal jaundice in Black South African newborn infants. *Transfusion* **21**, 744-749.

Declarations

Data Availability statement

All data generated or analyzed during the study are included in the manuscript.

Ethics approval and consent to participate

Not applicable **Consent for publication**

Not applicable

Funding

Not applicable

Conflict of Interest

Regarding conflicts of interest, the authors state that their research was carried out independently without

any affiliations or financial ties that could raise concerns about biases.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licen ses/by/4.0/. © The Author(s) 2023